A Multi-center, Open-label Study Assessing the Safety, Efficacy and Pharmacokinetics of 8 Week's Treatment of SPP100 (Aliskiren) Regimen in Hypertensive Patients With Renal Dysfunction.

Trial Profile

A Multi-center, Open-label Study Assessing the Safety, Efficacy and Pharmacokinetics of 8 Week's Treatment of SPP100 (Aliskiren) Regimen in Hypertensive Patients With Renal Dysfunction.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 May 2016

At a glance

  • Drugs Aliskiren (Primary)
  • Indications Hypertension
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 07 Nov 2011 Actual initiation date changed from Oct 2007 to Apr 2006 as reported by ClinicalTrials.gov.
    • 07 Nov 2011 Actual end date (May 2007) added as reported by ClinicalTrials.gov.
    • 03 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top